



AdVax

Cambridge Innovation Center
4240 Duncan Avenue
St. Louis, MO 63110
(314) 272-2363
www.ad-vax.com

*“Microbiome-sparing solutions for
Alzheimer’s & cardiovascular disease”*

COMPANY OVERVIEW

AdVax is a discovery and holding company that is partnered with Biological Mimetics to develop first-in-man vaccines, monoclonal antibodies, and nanobodies in the emerging multi-billion dollar arena of oral-systemic biology.

Advax is developing:

- Next-generation prophylactic, microbiome-sparing vaccines for the red complex oral pathogens that directly and substantially impact Alzheimer’s disease, cardiovascular disease, stroke, diabetes, osteoarthritis, and pre-term births
- Interdisciplinary licensable oral management systems directed at highly pathogenic oral bacteria. Systems delay onset by five years and reduce healthcare costs by 50%
- Paradigm changing diagnostics and monoclonal antibody-based therapeutics

OUR STORY

Over the years, Dr. Dan Sindelar would notice his 80- and 90-year old patients that were living full, active lives all had the “gums of a 16 year old.” This started him on the journey in defining oral-systemic biology.

At the same time, Dr. Garth Ehrlich was co-developing the biofilm concept with the late Bill Costerton, and Dr. Peter Nara was involved with developing and patenting Immune Refocusing Technology at DARPA.

Meanwhile in Switzerland, Dr. Judith Miklossy had just published research on pathogens of oral origin playing a causative role in Alzheimer’s disease.

Through the accident of purpose, these four unlikely partners have joined forces to develop and create microbiome-sparing solutions for Alzheimer’s disease and cardiovascular diseases.

INTELLECTUAL PROPERTY

The principals of AdVax own, hold, and are deriving most if not all of the intellectual property needed to complete all stages of pre-clinical and clinical development. In addition, the scientific and technical capabilities and know-how reside in the principals; to date the company has complete freedom to operate in the domains necessary for the discovery and commercialization of these bio-pharmaceuticals.

ADVAX

Company Profile

<http://ad-vax.com>

Industry: Biotechnology

Founded: 2014

Contact

Daniel L. Sindelar, DMD

drd@oralgenomics.com

(314) 272 – 2363

Financial Information

Stage: In Development/Pre-Clinical

Seeking Capital:

- Seed: \$500 Thousand
- Series A: \$2-5 Million

The Return

Multiple exits—Phase 1, Phase 2a/b

Value inflection points—Discovery, IND filing, Phase 1, Phase 2

Management

Peter Nara, MSc, DVM, PhD, FAAAS

Garth Ehrlich, PhD, FAAAS

Judith Miklossy, MD, PhD

Daniel Sindelar, DMD

SCIENCE/TECHNOLOGY

Oral Systemic Biology

Most people, despite socio-economic conditions, acquire chronic infections with pathogenic oral bacteria, which quickly adopt the biofilm mode of growth. During biofilm growth and chronic inflammation, they express specific local and systemic inflammatory mediators, which lead to pathology and disease.

Next-Level Sequencing & Cataloguing

The Distributed Genome Hypothesis which teaches that bacterial species possess a population-level supragenome that contains a large set of distributed genes, a subset of which are virulence factors which can serve as intervention targets for surgical-level precision for the removal of virulent strains without affecting the overall species-level microbiome composition

Targeting & Development

We stand alone in developing the Distributed Genome Hypothesis, discovering the science of Deceptive Imprinting and imagining and creating the patent-protected Immune Refocusing Technology. Collectively, these theoretical and practical advances provide AdVax with a market-leading position.

FUNDS SOUGHT & USAGE

To this date, AdVax has been self-funded with a small vested ownership team, allowing for exceptional investment opportunities.

Multiple seed and Series A funding opportunities are being sought for the company's financing of both the development of novel point of care diagnostics worth \$100s of millions per year and monoclonal antibodies and vaccines worth more than \$1-2 billion per year.

Seed: Raising \$500 Thousand for next-level sequencing, molecular cataloguing, and targeting

Series A: Seeking \$2-5 Million for Development of Nanobodies, Monoclonal Antibodies, and Vaccines

To most cost effectively advance the investment for timely exits, two programs are contemplated for creating value in the company in the shortest time possible.

MANAGEMENT

PETER LLOYD NARA, MSc, DVM, PhD, FAAAS - VACCINOLOGY

Deceptive Imprinting/Immune Refocusing Technology

President & CEO, Biological Mimetics, Inc.

GARTH EHRLICH, PhD, FAAAS – SYSTEMIC MICROBIOLOGY & GENOMICS

Theoretical Modeler of Chronic Bacterial Infections: Developer of the Mucosal Biofilm Paradigm, the Distributed Genome Hypothesis, and the Rubric of Bacterial Plurality
Professor of Microbiology and Immunology & Executive Director, Center for Genomic Sciences at Drexel University, College of Medicine

JUDITH MIKLOSSY, MD, PhD, DSc – NEUROPATHOLOGY, NEUROLOGY, PSYCHIATRY

Founder and Director of the Alzheimer's Prevention International Foundation
Director of the International Alzheimer Research Center in Switzerland

DANIEL L. SINDELAR, DMD

Innovator in developing oral-systemic biology
Co-founder and recent president of the American Academy for Oral Systemic Health (AAOSH)
Founder and director of Oral Genomics, LLC.